Successful treatment of sorivudine-related agranulocytosis with granulocyte-colony stimulating factor.
D000368:Aged; D000380:Agranulocytosis / Q000188:drug therapy*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000009:adverse effects*; D001086:Arabinofuranosyluracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D016179:Granulocyte Colony-Stimulating Factor; D001086:Arabinofuranosyluracil; C031368:sorivudine; D005472:Fluorouracil